Elypta is developing an exceptionally accurate blood and urine test for multiple cancer indications. Elypta’s liquid biopsy platform is based on the measurement and analysis of 20 metabolites, glycosaminoclycans, tracking a vital process in cancer. Machine learning is used to define and improve cancer-type specific signatures. Studies show exceptional accuracy in renal cell carcinoma but also other indications with multiple trials currently in progress. Applications range from early detection of disease to surveillance of recurrence and monitoring or prediction of treatment response, ultimately improving outcomes for cancer patients.

Karl Bergman





"The entire ecosystem"

You have the entire ecosystem at SUP46 – you have smart people hanging there, you have the investors and you also have media there. It has been really good for us in terms of getting attention to be at SUP46.

Become a SUP46 member

We accept startups based all over Sweden as members at SUP46 and have different types of memberships depending on the needs of your startup.

Apply now